6 completed, 2 not yet recruiting, 2 recruiting, 1 unknown. 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Not yet recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
Follow Postthrombotic Syndrome: new trials by email Literature Review of Postthrombotic Syndrome trials Research Report on Postthrombotic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) Colchicine 0.5 mg po, Placebo 0.5 mg po - Venous Thromboembolism | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 150 | 2025-07-07 | 2026-07-23 |
| Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease Placebo plus immunosuppression, Rivaroxaban plus immunosupression - Behcet Disease, Behcet Disease and Vascular Involvement | Phase 3 | Not yet recruiting | Marmara University | 110 | 2025-04-30 | 2025-04-13 |
| The MUFFIN-PTS Trial Micronized Purified Flavonoid Fraction, Placebo - Post-Thrombotic Syndrome | Phase 3 | Unknown | Sir Mortimer B. Davis - Jewish General Hospital | 88 | 2022-02-04 | 2023-11-30 |
| Statins for Venous Event Reduction in Patients With Venous Thromboembolism Rosuvastatin Calcium, Placebo Oral Tablet - Venous Thromboembolism, Blood Clot | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 2700 | 2021-02-10 | 2026-01-15 |
| Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis Hydroxyethylrutoside - Deep Vein Thrombosis | Phase 3 | Completed | Maastricht University Medical Center | 44 | 2020-12-08 | 2024-03-01 |
| Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy - Deep Vein Thrombosis, Post-Thrombotic Syndrome | Phase 3 | Withdrawn | University of Colorado, Denver | 2018-07-01 | 2018-08-10 | |
| Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Recombinant tissue plasminogen activator (rt-PA) - Deep Vein Thrombosis, Venous Thrombosis | Phase 3 | Completed | Washington University School of Medicine | 692 | 2009-11-01 | 2018-03-29 |
| Evaluation of the Duration of Therapy for Thrombosis in Children Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention - Venous Thrombosis | Phase 3 | Completed | Johns Hopkins All Children's Hospital | 532 | 2008-03-01 | 2025-06-18 |
| The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome Knee-length, graduated elastic compression stocking, Knee-length, placebo stocking - Deep Venous Thrombosis | Phase 3 | Completed | Sir Mortimer B. Davis - Jewish General Hospital | 806 | 2004-06-01 | 2014-08-18 |
| Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial Veno-device (Venowave) - Postphlebitic Syndrome | Phase 3 | Completed | Hamilton Health Sciences Corporation | 32 | 2004-05-01 | 2008-07-22 |
| Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities unfractionated heparin, Tinzaparin (Leo) - Deep Venous Thrombosis | Phase 3 | Completed | Aalborg University Hospital | 99 | 1993-10-01 | 2008-03-05 |
Venous Thrombosis (9) · Venous Thromboembolism (5) · Postphlebitic Syndrome (3) · Thrombosis (3) · Inflammation (2) · Behcet Syndrome (1) · Venous Insufficiency (1)
Cardiovascular Diseases (12) · Embolism and Thrombosis (12) · Vascular Diseases (12) · Venous Insufficiency (11) · Thrombosis (9) · Thromboembolism (5) · Peripheral Vascular Diseases (3) · Phlebitis (3) · Venous Thrombosis (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases (1) · Genetic Diseases, Inborn (1) · Hereditary Autoinflammatory Diseases (1)
Colchicine (2) · Tissue Plasminogen Activator (2) · Heparin (1) · Hydroxyethylrutoside (1) · Immune Tolerance (1) · Immunosuppression Therapy (1) · Rivaroxaban (1) · Rosuvastatin Calcium (1) · Tablets (1) · Tinzaparin (1) · troxerutin (1)
Ottawa Hospital Research Institute (2) · Sir Mortimer B. Davis - Jewish General Hospital (2) · Aalborg University Hospital (1) · Azienda Sanitaria Locale ASL 6, Livorno (1) · Hamilton Health Sciences Corporation (1) · Johns Hopkins All Children's Hospital (1) · Maastricht University Medical Center (1) · Marmara University (1) · University of Colorado, Denver (1) · Washington University School of Medicine (1)
Canada (6) · United States (3) · Netherlands (2) · Australia (1) · Austria (1) · Denmark (1) · France (1) · Ireland (1) · Israel (1) · Italy (1) · Norway (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Benedicte Laursen, MD, DMSc (1) · Clive Kearon, MB, MRCP, FRCP(C), PhD (1) · Fatma Alibaz-Oner, Prof (1) · Jean-Philippe Galanaud, MD, PhD (1) · Marc Carrier, MD,MSc,FRCPC (1) · Marilyn J Manco-Johnson, MD (1) · Martin O'Donnell, MB MRCPI (1) · Neil A Goldenberg, MD, PhD (1) · Samuel Z Goldhaber, M.D. (1) · Suresh Vedantham, M.D. (1) · Susan R Kahn, MD FRCPC (1) · Susan R Kahn, MD, MSc (1) · Susan R. Kahn, M.D., M.Sc. (1)
PMID 20047905, PMID 23537968, PMID 24315521, PMID 25183442, PMID 29211671, PMID 30586751, PMID 30699446, PMID 31354089, PMID 31592728, PMID 31843251, PMID 33445952, PMID 34518263, PMID 35015038, PMID 39321425, PMID 39968829
U01HL088476 (1), U01HL130048 (1)